Type 1 Diabetes and Its Physiology

Talca Imran*

Department of Pharmacy, BGC Trust University Bangladesh, Bangladesh

Corresponding Author*

Talca Imran

Department of Pharmacy, BGC Trust University Bangladesh, Bangladesh

E-mail: talca.ti@imran.com

Received: 01-July-2024, Manuscript No. jdm-24-33255; **Editor assigned:** 03-July-2024, PreQC No. jdm-24-33255; **Reviewed:** 17-July-2024, QC No. jdm-24-33255; **Revised:** 21-July-2024, Manuscript No. jdm-24-33255; **Published:** 28-July-2024, DOI: 10.35248/2155-6156.10001140

Abstract

Background: Type-1 diabetes (T1D) is an autoimmune disease characterized by the destruction of pancreatic beta cells, resulting in absolute insulin deficiency. This condition requires lifelong management to maintain glucose homeostasis and prevent complications.

Objective: This article explores the physiology of T1D, focusing on the mechanisms of beta-cell destruction, the role of genetic and environmental factors, and current management strategies.

Results: T1D is caused by an autoimmune response that targets insulin-producing beta cells. Genetic susceptibility, influenced by HLA gene variants and environmental triggers contribute to the disease's onset. Insulin deficiency leads to chronic hyperglycemia and metabolic disturbances, including diabetic ketoacidosis. Management strategies include insulin therapy, lifestyle modifications, and emerging immunotherapies and beta-cell replacement techniques.

Conclusion: Understanding the physiological mechanisms of T1D is crucial for effective management and the development of novel therapies. Advances in insulin delivery systems, immunotherapy, and beta-cell replacement hold promise for improving the quality of life and outcomes for individuals with T1D.

Keywords: Type-1 diabetes; Autoimmune disease; Beta-cell destruction; Insulin deficiency; Hyperglycemia; Diabetic ketoacidosis; Insulin therapy; Genetic susceptibility; Environmental triggers; Immunotherapy; Beta-cell replacement

Introduction

Type-1 diabetes (T1D) is a chronic autoimmune condition characterized by the destruction of insulin-producing beta cells in the pancreas. Unlike Type-2 diabetes, which is associated with insulin resistance and often linked to obesity and lifestyle factors, T1D results from an immune-mediated process leading to absolute insulin deficiency? This article delves into the physiology of T1D, the mechanisms underlying its development, and current management strategies [1].

Physiology of Type-1 diabetes

Autoimmune Destruction of Beta Cells: T1D is primarily an autoimmune disorder where the body's immune system mistakenly targets and destroys pancreatic beta cells, which are responsible for producing insulin. This destruction is mediated by autoreactive T-cells, particularly CD8+ cytotoxic T-cells, which infiltrate the islets of Langerhans and cause beta-cell apoptosis.

Genetic and environmental factors:

Genetic susceptibility: Certain genetic markers, particularly those in the HLA (human leukocyte antigen) region, are associated with an increased risk of T1D. These genetic predispositions influence the immune system's ability to distinguish between self and non-self [2].

Environmental triggers: Environmental factors, such as viral infections (e.g., enteroviruses), early exposure to cow's milk, and other dietary factors, may trigger the autoimmune response in genetically susceptible individuals. The exact triggers remain a topic of ongoing research.

Insulin production and glucose homeostasis: In a healthy individual, beta cells in the pancreas produce insulin in response to elevated blood glucose levels. Insulin facilitates the uptake of glucose into cells for energy production and storage. In T1D, the loss of beta cells results in insufficient insulin production, leading to chronic hyperglycemia (high blood sugar levels) [3].

Metabolic consequences of insulin deficiency

Hyperglycemia: Without adequate insulin, glucose remains in the bloodstream, causing persistent hyperglycemia. This condition leads to polyuria (frequent urination), polydipsia (excessive thirst), and polyphagia (increased hunger).

Ketosis and ketoacidosis: In the absence of insulin, the body cannot use glucose effectively for energy and starts breaking down fats, leading to the production of ketone bodies. Excessive ketone production can result in diabetic ketoacidosis (DKA), a life-threatening condition characterized by high blood acidity, dehydration, and electrolyte imbalances [4].

Management of Type-1 diabetes

Insulin therapy:

Basal-bolus regimen: This involves a combination of long-acting (basal) insulin to maintain baseline glucose levels and rapid-acting (bolus) insulin to manage postprandial (after-meal) glucose spikes.

Insulin pumps and continuous glucose monitoring (CGM): Advanced technologies such as insulin pumps and CGM systems offer more precise insulin delivery and real-time glucose monitoring, improving glycemic control and reducing the risk of complications [5].

Lifestyle and dietary management

Carbohydrate counting: Accurate estimation of carbohydrate intake helps adjust insulin doses to match the body's needs, preventing hyperglycemia and hypoglycemia.

Regular physical activity: Exercise improves insulin sensitivity and helps maintain overall health. However, individuals with T1D must carefully manage their insulin and carbohydrate intake to prevent exercise-induced hypoglycaemia [6].

Immunotherapy and beta-cell replacement

Immunotherapy: Research is ongoing to develop therapies that modulate the immune system to halt or reverse the autoimmune process in T1D. Monoclonal antibodies and other immunomodulatory agents are being investigated in clinical trials.

Islet transplantation and stem cell therapy: These approaches aim to restore insulin production by replacing destroyed beta cells. While promising, these therapies are still in experimental stages and face challenges such as immune rejection and the need for lifelong immunosuppression [7].

Results

Autoimmune destruction of beta cells

Mechanisms: The autoimmune response in T1D targets pancreatic beta cells, primarily mediated by autoreactive CD8+ T-cells. This immune attack leads to beta-cell apoptosis and progressive insulin deficiency.

Genetic factors: Genetic predisposition, especially HLA gene variants, significantly increases the risk of developing T1D. These genetic markers influence the immune system's capacity to differentiate self from non-self [8].

Environmental factors: Environmental triggers such as viral infections (e.g., enteroviruses), early exposure to cow's milk, and dietary factors contribute to the onset of T1D in genetically susceptible individuals.

Metabolic consequences of insulin deficiency

Hyperglycemia: The absence of sufficient insulin leads to chronic hyperglycemia, characterized by elevated blood glucose levels. Symptoms include polyuria, polydipsia, and polyphagia [9].

Ketosis and diabetic ketoacidosis (DKA): Due to inadequate insulin, the body resorts to fat breakdown for energy, leading to the production of ketone bodies. Excessive ketone production can result in DKA, a severe condition marked by high blood acidity, dehydration, and electrolyte imbalances.

Management strategies

Insulin therapy: Effective management of T1D involves a combination of basal (long-acting) and bolus (rapid-acting) insulin. Advanced technologies such as insulin pumps and continuous glucose monitoring (CGM) systems enhance glucose control and reduce complication risks.

Lifestyle and dietary management: Carbohydrate counting and regular physical activity is essential components of T1D management. These strategies help maintain glycemic control and overall health [10].

Emerging therapies: Immunotherapy aims to modulate the immune system and prevent further beta-cell destruction. Beta-cell replacement techniques, including islet transplantation and stem cell therapy, offer potential solutions for restoring insulin production, although they are still in experimental stages.

Conclusion

Type-1 diabetes is a complex autoimmune disease with significant implications for glucose homeostasis and overall health. Understanding the physiological mechanisms behind T1D is crucial for developing effective management strategies and advancing research towards a potential cure. Current management focuses on insulin therapy, lifestyle modifications, and emerging immunotherapeutic approaches to improve the quality of life for individuals living with T1D.

References

1. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380: 347-357.
2. Vlado P, Meg JJ, Bruce N, Severine B, Heerspink HJL, et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380: 2295–2306.
3. Heerspink HJL, Steffansson BV, Correa-Rotter R, Chertow GM, Greene T, et al. (2020) Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383:1436-1446.
4. Wanner C, Inzucchi S, Lachin JM, Fitchett D, von Eynatten M, et al. (2016) Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375: 323-334.
5. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, et al. (2015) Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 38: 1687–1693.
6. Rosenstock J, Ferrannini E (2015) Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern with SGLT2 Inhibitors. Diabetes Care 38: 1638–1642.
7. Dandona P, Mathieu C, Phillip M, Hansen L, Tschöpe D, et al. (2018) Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT-1 52-Week Study. Diabetes Care 41: 2552–2559.
8. McCrimmon RJ, Henry RR (2018) SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia 61: 2126–2133.
9. Li K, Xu G (2019) Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials. J Diabetes 11: 645–655.
10. Abdul-Ghani M, Puckett C, Triplitt C, Maggs D, Adams JA, et al. (2018) Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study. Diabetes 67: 123.

Cite this article: Talca Imran. Type 1 Diabetes and Its Physiology. J Diabetes Metab, 2024, 15(7): 1140.